I've asked Anna from walbrook but received an auto reply instead stating she is out till 10th oct. Just wanted to find out if this tech poses an existential threat for Xenoview. Company never replies directly anyway. Extremely disappointing and frustrating.
Didn't understand a line she was saying. I thought it was an Australian company.
https://www.cyclopharm.com/
Lots of big sells are going through. It seems the market is convinced polx is destined to fail, I hope not but the next raise would be extremely painful for the remaining shareholders. It is company's duty to protect it's shareholders and deliver. It seems they have forgotten it and enjoying their more than generous wages and ready to get their begging bowl out soon. Shame: (
"Hopefully a lot of the hospitals chose the safest option for patients and staff, with a great ROI, then we should be okay"
I used to as optimistic as you are mate but millions of hospitals are still using xray and other radio active scans so it seems cost would be the main factor to decide. Since this management has failed to generate any interest in new sale, it seems this tech is either destined to fail or somebody to buy them for peanuts out of administration. Eitherway it's another disaster for loyal shareholders like us. That 150K daily seller is not going to stop so it will keep going down and down.
The CEO still doesn't hold any shares so it's not his headache to do anything to boostup the sentiment or SP. Not sure if the CFO holds any either. Really sad times ahead.
"The commercial rollout will begin immediately, McBrayer said, noting that the company will now complete final assembly of its first wave of 200 generators, with plans for the first air shipments to arrive in the U.S. by early November. Cyclopharm will leverage the company’s sales and operational expertise across 64 countries globally in which the product is already approved and established.
U.S. reimbursement codes are based on established nuclear medicine procedures, which means Technegas can be immediately reimbursed under existing bundled procedural codes for $140 per patient."
Pent-up demand in the U.S.
Physicians have been waiting on the approval for so long in the U.S., and there's a “pent up demand,” the CEO said, adding that the U.S. is “behind the rest of the world” in imaging the lung, because Technegas has displaced older technologies, such as Xenon-133 and technetium DTPA, a wet aerosolized nuclear imaging agent.
https://www.bioworld.com/articles/701482-fda-approves-cyclopharms-technegas-combo-product-for-visualizing-pulmonary-ventilation
Polarean uses Xe-129 which is non radioactive, that's the only difference but this new tech is much much cheaper than Xenoview. Even I'm in double mind now. Management's silence is just totally unacceptable.
Wise move andrew99
I read your post and thought I post my observation on this matter so here it goes:
I dont have a second account
Ans: Mate, nobody cares if you have four five accounts.
Chris I have had my eye on this for a while
Ans: Are you stalking him?
The fact is it has done nothing but drop and you have done nothing but shout about the upside
Ans: Chris holds FAB so he is promoting his stock. You can always filter him if you don’t like it, why launching personal attacks?
I think you are blinded by it
Ans: He owns the stock so he is biased.
The chart is clearly indicating a huge drop below 5p
Ans: Always use “in my opinion”. RSI is nearly oversold territory so it can jump with news anytime. I have respect for Noel but he was proven wrong countless times so don’t just follow him blindly. Chartist don’t understand fundamentals, never will!
I'll not post any more on here but just remember it was me that told you and others about AVCT the hundred bagger so we will let history decide who gave the better advice
Ans: Good and please stop cross ramping your stocks, it never works, never will. AVCT is need of funds and will do a FAB like fund raise sooner or later. Also its nearly in overbought territory on RSI. There is big twitter AVCT following which is allowing it have fairly strong liquidity. Wait for the funding news, it will crash like a falling knife.
Dont be fooled by its 300m market cap. It is high for good reason and yes it absolutely is a hundred bagger.
Ans: People who are interested in AVCT and happy with it’s risk vs reward profile will buy no matter what the market cap is. Just count how many zeros it will need to become a hundred bagger company first. I thought the same much better company than AVCT but it never happened. But I wish you all the best.
You think cos fab is cheap it is better and its just not true
Ans: FAB is a different business, it’s not doing what AVCT is doing, it’s a not a like for like comparison so please stop doing that. It’s much easier for a sub £4M company to double to tribble than a £300M highly speculative company to double to tribble. You want to promote AVCT, please do it on AVCT board, NOT here, please!
GL if staying in here as you will need it
Ans: You posted "Strong sell" opinion on FAB so we get it. Thank you
It's a fantastic news for AVCT investors. This is not a like for like comparison, is it? One could say LLAI multibagged from 20p to over 100p in last few months alone, will you say LLAI is better than AVCT?
FAB is not developing any drugs instead it giving companies the tools they need to develop theirs much quicker, efficiently. Traders are trading it like the way like atm but if the company start getting new contracts then it will simply fly IMHO.
I wish you all the best.
JohnHenry
I'm quite familiar with their story so please watch RH's investors presentation when he was the CEO and confirmed they will need funds again by June 2024 so what this CEO is claiming that they have reduced their operating cost to have a cash runway until Q2 2024 is somewhat misleading. It was always the case, he didn't actually do much.
Listen, I want the company to succeed very much just like anybody else but given their dire situation with cancelled market guidance, it might rerate post fund raise which will be good news anybody buying during/after fund raise. I suspect Nukem, Bracco will probably participate but will claim a bigger discount. Given Amati sold 2M shares not that long, they might bail at some point.